Related Experiment Video
Updated: Aug 19, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Inhibition of human neuroblastoma cell growth by CAY10404, a highly selective Cox-2 inhibitor
Bhupesh Parashar1, Sai Latha Shankar, Kathleen O'Guin
1Department of Radiation Oncology, Montefiore Medical Center, Bronx, NY 10461, USA.
Abstract:
Neuroblastomas constitute about 10% of childhood cancers and are responsible for 15% of pediatric cancer mortality. We evaluated the efficacy and the mechanism of cell death induced by CAY10404, a selective cyclooxygenase-2 (Cox-2) inhibitor in four human neuroblastoma cell lines (SH-EP, SH-SY5Y, SK-N-MC and MSN). Treatment with CAY10404 in the range of 15-115 microM revealed a dose-dependent decrease in cell number and an average IC50 (inhibitory concentration 50%) of 60 microM. About 20-30% of the cells were terminal deoxynucleotidyltransferase-mediated UTP nick-end-labeling (TUNEL) positive 48 h after treatment. Western blot analysis of CAY10404-treated cells showed poly(ADP-ribose) polymerase (PARP) cleavage and cleaved caspase-3 signifying caspase activity and apoptotic cell death. Inhibitor-of-apoptosis proteins including X-linked inhibitor-of-apoptosis protein (XIAP) and survivin did not change significantly after CAY10404 treatment. Fluorescence activated cell sorter (FACS) analysis performed in two different cell lines 48 h following CAY10404 treatment showed a reduction in the number of cells in the G1 phase of the cell cycle and an increase in the number of cells in the G2 phase. When radioresistant SH-EP cells were treated with CAY10404, a 49% decrease in cell viability was observed relative to DMSO-treated cells; pretreatment with CAY10404 followed by ortho-voltage irradiation further enhanced cell death (58%) suggesting radiosensitization by CAY10404.
Insights
A selective cyclooxygenase-2 (Cox-2) inhibitor, CAY10404, effectively reduced neuroblastoma cell viability and induced apoptosis. This compound also demonstrated radiosensitizing effects, enhancing cell death when combined with irradiation.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Neuroblastomas are a significant cause of childhood cancer mortality, accounting for 10% of cases and 15% of deaths.
- Understanding novel therapeutic targets and mechanisms for neuroblastoma treatment is crucial.
Purpose of the Study:
- To evaluate the efficacy of CAY10404, a selective cyclooxygenase-2 (Cox-2) inhibitor, in human neuroblastoma cell lines.
- To elucidate the mechanism of cell death induced by CAY10404.
Main Methods:
- Treatment of four human neuroblastoma cell lines (SH-EP, SH-SY5Y, SK-N-MC, MSN) with CAY10404.
- Assessing cell viability, apoptosis (TUNEL, PARP cleavage, caspase-3 activity), cell cycle progression (FACS), and radiosensitization.
- Western blot analysis to detect protein cleavage indicative of apoptosis.
Main Results:
- CAY10404 demonstrated a dose-dependent decrease in cell number with an IC50 of 60 microM.
- Apoptotic cell death was confirmed by TUNEL positivity, PARP cleavage, and increased caspase-3 activity.
- CAY10404 treatment led to cell cycle arrest in the G2 phase and showed radiosensitizing effects on radioresistant SH-EP cells.
Conclusions:
- CAY10404 effectively inhibits neuroblastoma cell growth and induces apoptosis through caspase activation.
- CAY10404 exhibits radiosensitizing properties, suggesting its potential as an adjuvant therapy in neuroblastoma treatment.
More Related Videos
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
05:29A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
Targeted Cancer Therapies
There are several types of targeted therapies against specific...